HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

2- (2- chloro- 4- iodophenylamino)- N- 3,4- difluorobenzoic acid

Also Known As:

ATR-002; ATR002

Networked: 4 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Planz, Oliver: 3 articles (01/2022 - 01/2018)
2.	Ludwig, Stephan: 2 articles (01/2022 - 01/2018)
3.	Brunotte, Linda: 1 article (01/2022)
4.	Faist, Aileen: 1 article (01/2022)
5.	Hoffmann, Helen: 1 article (01/2022)
6.	Hoffmann, Markus: 1 article (01/2022)
7.	Hrincius, Eike: 1 article (01/2022)
8.	Mecate Zambrano, Angeles: 1 article (01/2022)
9.	Pöhlmann, Stefan: 1 article (01/2022)
10.	Rescher, Ursula: 1 article (01/2022)

Related Diseases

1.	Infections 01/01/2018 - "aureus titres in vitro during super-infection in the presence and absence of the drugs and characterized the direct impact of ATR-002 on bacterial growth and phenotypic changes. " 01/01/2018 - "Importantly, neither CI-1040 nor ATR-002 treatment led to increased bacterial titres during super-infection, indicating that the drug does not sensitize cells for bacterial infection. " 01/01/2021 - "Improved in vitro Efficacy of Baloxavir Marboxil Against Influenza A Virus Infection by Combination Treatment With the MEK Inhibitor ATR-002."
2.	Human Influenza (Influenza) 01/10/2022 - "We demonstrate that ATR-002, a specific inhibitor of the upstream MEK1/2 kinases which is currently evaluated in clinical trials as an anti-influenza drug, displays strong anti-SARS-CoV-2 activity in cell lines as well as in primary air-liquid-interphase epithelial cell (ALI) cultures, with a safe and selective treatment window. "
3.	COVID-19 01/10/2022 - "Thus, our data suggest that the Raf/MEK/ERK signaling cascade may represent a target for therapeutic intervention strategies against SARS-CoV-2 infections and that ATR-002 is a promising candidate for further drug evaluation." 01/10/2022 - "We also observe that ATR-002 treatment impairs the SARS-CoV-2-induced expression of pro-inflammatory cytokines, and thus might prevent COVID-19-associated hyperinflammation, a key player in COVID-19 progression. " 08/25/2022 - "Treatment combinations of ATR-002 with nucleoside inhibitors Molnupiravir and Remdesivir or 3C-like protease inhibitors Nirmatrelvir and Ritonavir, the ingredients of the drug Paxlovid, were examined in Calu-3 cells to evaluate the advantage of their combinatory use against a SARS-CoV-2 infection. "
4.	Bacterial Infections (Bacterial Infection) 01/01/2018 - "However, it remained unclear if this inhibitor and its active form, ATR-002, might sensitize host cells to either IV or secondary bacterial infections. " 01/01/2018 - "Importantly, neither CI-1040 nor ATR-002 treatment led to increased bacterial titres during super-infection, indicating that the drug does not sensitize cells for bacterial infection. "

Related Drugs and Biologics

1.	Mitogen-Activated Protein Kinase Kinases (MEKs)
2.	baloxavir
3.	Phosphotransferases (Kinase)
4.	Ritonavir (Norvir)
5.	Cytokines
6.	Protease Inhibitors (Protease Inhibitor)
7.	Nucleosides
8.	2- (2- chloro- 4- iodophenylamino)- N- cyclopropylmethoxy- 3,4- difluorobenzamide
9.	nirmatrelvir and ritonavir drug combination
10.	nirmatrelvir